TippingPoint Biosciences

Executive Summary

TippingPoint Biosciences is a preclinical-stage biotechnology company pioneering novel small molecule therapies for diseases of chromatin dysfunction, with a primary focus on pediatric diffuse midline glioma (DMG), a devastating brain cancer with no approved targeted treatments. Founded in 2018 and based in Cambridge, Massachusetts, the company leverages deep expertise in chromatin biology to develop first-in-class therapeutics that address fundamental epigenetic drivers of cancer. Despite being in early stages, TippingPoint's approach has the potential to transform outcomes for patients with high unmet medical needs. The company is actively advancing its lead program toward IND-enabling studies and is expected to seek partnership or financing to support clinical translation.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead DMG Program40% success
• Q3 2026Presentation of Preclinical Efficacy Data at Major Conference70% success
• Q2 2026Series A or B Financing Round60% success